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Abstract
Introduction: Adrenal steroidogenesis is essential for human survival and depends on the availability of the precursor
cholesterol. Male subjects with low plasma levels of high density lipoprotein (HDL) cholesterol are characterized by
decreased adrenal function. Whether this is also the case in female subjects with low plasma HDL-C levels is unresolved to
date.
Findings: 15 female ATP binding cassette transporter AI (ABCAI) and 14 female lecithin-cholesterol acyltransferase (LCAT)
were included in the study. HDL-C levels were 38% and 41% lower in ABCA1 and LCAT mutation carriers compared to
controls, respectively. Urinary steroid excretion of 17-ketogenic steroids or 17-hydroxy corticosteroids did not differ
between 15 female ABCA1 mutation carriers (p = 0.27 vs 0.30 respectively) and 30 matched normolipidemic controls or
between 14 female LCAT mutation carriers and 28 matched normolipidemic controls (p = 0.10 and 0.14, respectively).
Cosyntropin testing in an unselected subgroup of 8 ABCA1 mutation carriers and 3 LCAT mutation carriers did not reveal
differences between carriers and controls.
Conclusion: Adrenal function in females with molecularly defined low HDL-C levels is not different from controls. The
discrepancy with the finding of impaired steroidogenesis in males with molecularly defined low HDL-C levels underscores
the importance of gender specific analyses in cholesterol-related research.
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Introduction
The adrenal gland plays a pivotal role in essential physiological
processes such as the regulation of stress response, blood pressure
and electrolyte homeostasis. Cholesterol is the substrate for
adrenal steroidogenesis and is for 75% derived from plasma
lipoproteins [1], [2]. However, whether the availability of
lipoprotein derived cholesterol is a rate-limiting factor for adrenal
steroidogenesis in humans is sparsely investigated to date.
The importance of low density lipoprotein (LDL) derived
cholesterol for adrenal steroidogenesis has been studied in patients
with familial hypercholesterolemia (FH), carrying mutations in the
LDL receptor (LDLR). The adrenal gland takes up plasma
cholesterol via endocytosis of the LDL receptor [3]. In line with
this notion, adrenal steroidogenesis is impaired in homozygous
LDLR mutation carriers [4] and homozygous apolipoprotein B
(APOB) mutation carriers, suffering from genetically impaired
binding of LDL to the LDL receptor [5], [6], [7]. Heterozygous
LDLR and APOB carriers, however, did not show any signs of
impaired adrenal steroidogenesis [5], [8]. Together, these studies
indicate that plasma lipoprotein derived cholesterol plays a role in
adrenal steroidogenesis, but that LDL derived cholesterol does not
constitute the major source of substrate for the adrenal glands.
High density lipoprotein (HDL) has been suggested to be the
preferred lipoprotein for cholesterol delivery to the adrenal gland
in adrenal cell lines [9] and in murine models [10], [11], [12],
[13], [14], [15]. In critically ill patients, low HDL-C levels are
associated with impaired adrenal responses to synthetic ACTH
[16]. Furthermore, others reported a high incidence of adrenal
failure in critically ill individuals, with HDL-C being the only
variable predictive of adrenal insufficiency [17].
Importantly, adrenal function was assessed in individuals with
functional mutations in SCARB1, the gene encoding the HDL
receptor Scavenger Receptor B1, which is highly expressed on the
adrenal gland. Heterozygous SRB1 mutation carriers display
markedly decreased adrenal steroidogenesis [18]. Furthermore, we
recently demonstrated that male individuals with low plasma
HDL-C levels are characterized by decreased adrenal function
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e90967
[19], further underlining the importance of HDL derived
cholesterol for adrenal steroidogenesis. However, whether adrenal
steroidogenesis is also impaired in females with low plasma HDL-
C remains to be investigated.
We set out to assess adrenal function in female carriers of
functional mutations in ATP-binding cassette transporter A1
(ABCA1) and lecithin-cholesterol acyltransferase (LCAT), typically
displaying half-normal plasma levels of HDL-C. We hypothesized
that in female subjects with low HDL-C levels, adrenal function is
compromised irrespective of the molecular origin of the low HDL-
C levels.
Methods
Recruitment of Study Participants
Subjects with HDL-C levels ,5th percentile were screened for
mutations in ABCA1 and LCAT [20], [21]. Data were obtained in
parallel with a study on adrenal function in male ABCA1 and
LCAT mutation carriers [19]. For the current study, we enrolled
15 female carriers of mutations in ABCA1 and 14 female carriers of
mutations in the LCAT gene. Functionality of all mutations was
established in previously published studies [21], [22], [23]. As a
control group, normolipidemic age matched female individuals
were recruited by advertisement. In order to increase power,
carriers were matched to controls in a 1:2 fashion. None of the
included individuals used oral contraceptives or medication
interfering with steroid metabolism. The study was approved by
the institutional review board of the Academic Medical Center,
Amsterdam, The Netherlands. All participants provided written
informed consent.
Questionnaire and Biochemical Measurements
Medical history, cardiovascular risk factors and use of medica-
tion were assessed using a questionnaire. Brachial artery blood
pressures was measured using an oscillometric blood pressure
device (Omron 705IT, Hoofddorp, the Netherlands). Hyperten-
sion was defined as 1) use of antihypertensive medication and/or
2) a systolic blood pressure at visit above 140 mmHg and/or
diastolic blood pressure above 90 mmHg.
Plasma was obtained after an overnight fast and stored at 2
80uC. Total cholesterol, LDL-C, HDL-C and triglyceride levels
were analyzed using commercially available enzymatic methods
(Randox, Antrim, United Kingdom and Wako, Neuss, Germany)
on a Cobas Mira autoanalyzer (Roche, Basel, Switzerland).
Aldosterone was measured using a radioimmunoassay (Siemens,
Los Angeles, USA).
Baseline Adrenal Steroidogenesis
All study participants followed the same protocol to collect 24-
hour urine: on day 1, the first morning urine is not collected. After
the morning urine, all urine is collected in the container.
Participants collected urine for 24 hours, and ended with adding
the morning urine of day 2 to the container. Urinary excretion of
steroid metabolites was analyzed by gas chromatography in 24-
hour urine samples as previously described [24], [25]. Androsteron
(A), etiocholanolon (E), dehydroepiandrosteron (D), 11-keto-
androsteron (KA), 11-keto-etiocholanolon (KE), 11-hydroxy-
androsteron (HA), 11-hydroxy-etiocholanolon (HE), pregnaandiol
(P2), Pregnaantriol (P3), 11-deoxytetrahydrocortisol (THS), tetra-
hydrocortison (THE), tetrahydrocortisol (THF) and allo-tetrahy-
drocortisol (ALLO) were measured as readout of adrenal
steroidogenesis. A, E, D, KA, KE, HA and HE make up total
17-ketogenic steroids (17-KS), whereas THS, THE, THF, ALLO
and P3 are the constituents of total 17-hydroxycorticoids (17-
OHCS). In addition, urinary free cortisol was determined using
solid-phase extraction-liquid chromatography- tandem mass spec-
trometry on a Symbiosis Pharma (Spark Holland, Emmen, The
Netherlands) Quattro premier Tandem Mass spectrometer (Wa-
ters, Millford MA) system. Solid Phase extraction was performed
on Oasis HLB cartridges (Waters, Millford, MA), chromatograph-
ic separation was achieved on a Waters Sunfire C18 column
3.5 mm 2.1650 mm using ammonium acetate mM with 0.1%
formic acid as mobile phase and acetonitrile as mobile phase B.
Limit of detection 5 nmol/L, intra-assay variation ,4%, total
assay variation ,7%.
Stimulated Adrenal Steroidogenesis
Unselected subgroups of 8 ABCA1 and 3 LCAT mutation
carriers consented to an ACTH stimulation study (co-syntropin or
tetracosactin, 0.25 mg/ml, Novartis Pharma b.v., Arnhem, The
Netherlands). All the cosyntropin tests started strictly at 9.00 am.
All patients underwent an overnight fast prior to cosyntropin
testing. Two baseline blood samples were obtained, 15 minutes
and 1 minute before administration of the 1 mg cosyntropin bolus.
Subsequent blood samples were drawn 30 minutes and 60 minutes
after cosyntropin administration. Plasma cortisol levels were
measured by enzyme immunoassay (Siemens Medical Solutions,
Los Angeles, CA), and cortisol-binding globulin (CBG) levels were
measured with a commercial radioimmunoassay (Siemens Medical
Solutions, Los Angeles, CA). Free cortisol levels were calculated
using the method described by Coolens et al [26].
Statistical Analysis
Unpaired student’s T-test was performed for analysis of
continuous data with a normal distribution. In case of a skewed
distribution, data were log-transformed prior to T-testing.
Categorical data were assessed by x2-testing. A p-value of ,0.05
was considered statistically significant. Interaction analyses were




We enrolled 15 and 14 female carriers of loss of function
mutations in ABCA1 and LCAT, respectively. Three of the ABCA1
mutation carriers were either compound heterozygous or homo-
zygous, while two of the LCAT mutation carriers were homozy-
gous. None of the participants was referred to our clinic for
symptoms of adrenal dysfunction. Age-matched female family
members were asked to participate as controls. As an insufficient
number of family members volunteered, unrelated age-matched
female controls were recruited by advertisement. Demographic,
clinical and biochemical characteristics of all study participants are
listed in table 1. As expected, HDL-C levels were 38% lower in
carriers of ABCA1 mutations and 41% lower in LCAT mutation
carriers, compared to normolipidemic controls (p,0.001). Hyper-
tension was more prevalent in ABCA1 mutation carriers (p = 0.002)
and LCAT mutation carriers (p = 0.02). Systolic and diastolic blood
pressure was significantly higher in LCAT mutation carriers
compared to controls (p = 0.03 and p=0.03, respectively). Other
parameters did not differ significantly.
The significance of the interaction terms allows us to separately
assess adrenal steroidogenesis in male and female carriers.
Basal Adrenal Steroidogenesis
Twenty four hour urinary excretion of 17-ketogenic steroids
(17-KS) or 17-hydroxycorticosteroids (17-OHCS) did not differ
Adrenal Function in Females with Low HDL-C
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between carriers of mutations in ABCA1 and controls (p = 0.27 and
0.30, Figure 1a), or between LCAT mutation carriers and controls
(p = 0.10 and 0.14, Figure 1b). Urinary steroid excretions were
within the normal range for both for 17-KS and 17-OHCS [25].
The full panel of urinary steroid metabolites is presented in
figure 2a–b.
No gene-dose effect was observed when comparing the three
compound heterozygous/homozygous ABCA1 mutation carriers
or the two homozygous LCAT mutation carriers to heterozygous
carriers and controls.
Adrenal Response to Cosyntropin
In a 1 mg cosyntropin stimulation test, the cortisol response to
physiological levels of ACTH is measured as a proxy of adrenal
cortical function [27], [28]. The peak serum cortisol response to
Table 1. Characteristics of female ATP-binding cassette transporter 1 (ABCA1) and Lecithin-cholesterol acyltransferase (LCAT)
mutation carriers and matched female controls.
Characteristics ABCA1 LCAT
Controls (n = 30) Carriers (n = 15) p value Controls (n = 28) Carriers (n = 14) P value
Demographic
Age - yrs 48.1614.8 47.4614.5 0.88 41.4617.4 41.7615.2 0.99
BMI (kg/m2) 24.864.0 25.767.4 0.59 24.764.3 25.165.9 0.79
Current smokers - no (%) 4 (13) 2 (13) 1.00# 3 (10) 1 (25) 0.74#
Statin users - no (%) 3 (33) 6 (67) 0.10# 3 (38) 5 (63) 0.25#
Alcohol users - no (%) 19 (63) 8 (53) 0.52# 18 (62) 7 (50) 0.45#
Clinical
Coronary artery disease - no (%) 1 (3) 4 (27) , 1 (3) 0 ,
Diabetes mellitus - no (%) 0 1 (7) , 0 0 ,
Hypertension - no (%) 2 (7) 7 (47) 0.002# 1 (3) 4 (29) 0.02#
Systolic blood pressure (mmHg) 121.1616.9 136.1624.5 0.07 117.0610.1 130.2616.6 0.03
Diastolic blood pressur (mmHg) 73.0611.7 80.0610.2 0.10 71.9610.2 81.1610.2 0.03
Biochemical
Aldosterone (nmol/L) 0.1760.15 0.2660.22 0.23 0.1860.15 0.1760.14 0.88
Cortisol Binding Globulin (mg/L) 68.0640.8 65.362.5 0.86 68640.8 73.3641.3 0.85
Total cholesterol (mmol/L) 4.5061.10 4.4161.47 0.14 4.8261.12 4.3561.10 0.21
LDL cholesterol (mmol/L) 3.2361.03 3.2061.08 0.95 3.0761.07 3.0460.81 0.94
HDL cholesterol (mmol/L) 1.4360.34 0.8860.51 ,0.001 1.4860.36 0.8760.40 ,0.001
Triglycerides mmol/L 0.89 (0.65–1.28) 1.09 (0.71–1.63) 0.25 0.80 (0.60–1.21) 1.12 (0.68–1.64) 0.10
Values are means6 SD unless otherwise indicated. Triglycerides are median with interquartile range. P for Student’s T-test. Triglycerides were logtransformed prior to T-
test.
#P for x2 test. No t-test was performed for history of coronary artery disease since referral bias was present. Partial overlap exists between the two control cohorts.
doi:10.1371/journal.pone.0090967.t001
Figure 1. 24-hour urinary steroid excretion in male ABCA1 and LCAT mutation carriers compared to age-matched female controls.
Data are presented as mean 6 SD. P values for student’s t-test.
doi:10.1371/journal.pone.0090967.g001
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ACTH was not different between ABCA1 and LCAT mutation
carriers and did not differ from controls (p = 0.63 and 0.96,
respectively, figure 3a–b). In addition, peak plasma levels of free
cortisol, taking into account possible differences in cortisol binding
globulin (CBG) levels [18], were not different. Plasma lipid levels
did not differ significantly before and after cosyntropin testing
(data not shown).
Discussion
This study shows that adrenal steroidogenesis is not impaired in
female individuals with low plasma HDL-C levels. This is in
contrast with our earlier finding of lower basal urinary steroid
excretion in males with low plasma HDL-C levels. These findings
underline the differences between men and women in terms of
cholesterol metabolism and adrenal steroidogenesis and emphasize
the importance of gender-specific analyses in cholesterol related
research.
Studies showing decreased adrenal steroidogenesis in murine
models of compromised availability of HDL derived cholesterol
were carried out in both males [13], [14] and females [12]. These
studies did not report gender specific effects [12], [13], [14]. It
should be taken into account, however, that cholesterol metabo-
lism differs greatly between mice and men and, as a consequence,
results derived from murine models are not necessarily reflecting
human (patho)physiology. Human studies addressing this question
are sparse and data about the distribution of males and females are
lacking [18]. Interaction analyses, however, established a gender
specific effect of carriership on adrenal steroidogenesis. This is in
line with the fact that the reference values of our parameters are
gender specific [24], [25]. Furthermore, no articles on the role of
cholesterol in adrenal steroidogenesis pool data of males and
females [4], [5], [6], [7], [8].
Our findings constitute the first evidence of differential adrenal
cholesterol handling in males and females. Based on the current
data, we can only speculate about the mechanism underlying the
Figure 2. Urinary steroid metabolites in female ABCA1 and LCAT mutation carriers compared to age-matched female controls. Data
are presented as mean 6 SD. P values for student’s t-test.
doi:10.1371/journal.pone.0090967.g002
Figure 3. Peak serum cortisol increase after cosyntropin administration in female ABCA1 and LCAT mutation carriers versus female
controls. Data are presented as mean 6 SD. P values for Student’s T-test.
doi:10.1371/journal.pone.0090967.g003
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differential effect of low plasma HDL-C levels in men and women.
In murine models, there was no differential effect between male
and female animals, and, therefore, experiments in these
experimental models can not be expected to elucidate the
gender-dependent findings in humans.
Plasma HDL cholesterol levels are gender specific, as reflected
by different reference values for men and women [29]. Further-
more, the correlation between HDL-C levels with age is negative
in women, but positive in men [30]. The correlation between
HDL-C levels and cardiovascular disease has been described to be
gender specific. For example, plasma levels of LCAT were
associated with low HDL-C levels in men, but not in women.
Moreover, plasma LCAT levels were associated with a surprisingly
increased CHD risk in women, but not in men [31].
Gender-specific effects in adrenal function have also been
described. Different reference values are used for urinary
steroidogenesis in males and females [25]. Furthermore, females
have been shown to exhibit a stronger response to synthetic
ACTH than males [32]. However, neither explains the gender-
specific findings in our cohort.
Several mechanisms may explain the different effects of low
HDL cholesterol levels on adrenal steroidogenesis between men
and women. First, women are characterized by higher levels of
estradiol compared to men, which has shown to be essential in
maintaining an adequate adrenal output [33]. This may constitute
an additional stimulatory pathway, which men lack, equipping
women with sufficient adrenal stimuli to overcome the effects of
low availability of substrate. Conversely, men display higher levels
of androgens, which have shown to be associated with decreased
adrenal function [34], indicating that men not only lack the
stimulatory effects of estrogen on adrenal steroidogenesis, but have
an inhibitory pathway instead. On top of low levels of HDL-
derived cholesterol, this may compromise adrenal steroidogenesis
in males, whereas females are relatively protected.
Furthermore, the gender-specific differential effects may pertain
to differences in the immune system. Interleukin (IL) 6 is essential
for the activation of the hypothalamic-pituitary-adrenal axis [35],
[36]. IL6 expression is lower in males compared to females [37].
Given the fact that male adrenal steroidogenesis is more strongly
affected by plasma interleukin 6 (IL6) than female adrenal
steroidogenesis [38], this additional lack of adrenal stimulation
in low HDL males, may tip the balance to lower adrenal
steroidogenesis in males, whereas females both have higher IL6
expression and less dependence of adrenal steroidogenesis on IL6
levels.
Interestingly, hypertension was more prevalent in both ABCA1
and LCAT mutation carriers, but seemed better regulated in
ABCA1 mutation carriers. Increased prevalence of hypertension
has been previously reported in LCAT mutation carriers [39].
Given the absence of a difference in both plasma aldosterone levels
and adrenal function, an adrenal component is unlikely to
contribute to the increased hypertension in carriers.
A limitation of this study is the fact that moment in menstrual
cycle was not recorded, nor was pre- or postmenopausal state.
However, by closely matching study participants for age, the
chance was minimized that these age-related circumstances
influenced results. Furthermore, the study cohort was relatively
small, inherent to studies in subjects with rare mutations.
However, false-negative findings are unlikely given the small
differences between carriers and non-carriers: 21.29 gmol/24 h
for total 17-ketogenic steroids and 1.02 gmol/24 h for total 17-
hydroxycorticoids. For comparison, the difference in male carriers
compared to controls was 6.79 gmol/24 h for total 17-ketogenic
steroids and 4.85 gmol/24 h for total 17-hydroxycorticoids.
Alltogether, our data show that adrenal function in females with
molecular defined low HDL-C levels is not different from controls.
The discrepancy with the finding of impaired steroidogenesis in
males with molecularly defined low HDL-C levels, underscores the
importance of gender specific analyses in cholesterol related
research.
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